Abstract:The impact of delayed graft function (DGF) on the outcome of renal transplantation remains controversial. We analyzed the risk factors for DGF and its impact on graft and patient survival. A total of 354 renal transplants performed between June 1986 and April 2000 were analyzed. Variables analyzed included donor and recipient age, method and duration of renal replacement therapy, HLA mismatch, cold and warm ischemia times, biopsy-confirmed acute rejection, length of stay in the hospital, serum creatinine at th… Show more
“…The incidence of DGF is common in deceased donor transplants compared to living donor renal transplant recipients . With increasing laparoscopic donor nephrectomy and warm ischaemia time, the incidence of ATN has increased .…”
mentioning
confidence: 99%
“…4,5 The incidence of DGF is common in deceased donor transplants compared to living donor renal transplant recipients. 6 With increasing laparoscopic donor nephrectomy and warm ischaemia time, the incidence of ATN has increased. 7,8 Serum creatinine, a gold standard biochemical parameter for the laboratory diagnosis of kidney injury, increases late and after significant decline in glomerular filtration rate.…”
Serial uKIM-1 measurement can be used as non-invasive diagnostic biomarkers to predict the incident of DGF in living donor renal transplant recipients. At 18(th) post-transplant hour uKIM-1 can predict DGF with 100% specificity and 89.9% sensitivity with a cut-off value of normalized KIM-1 of 923.43 pg/mg.
“…The incidence of DGF is common in deceased donor transplants compared to living donor renal transplant recipients . With increasing laparoscopic donor nephrectomy and warm ischaemia time, the incidence of ATN has increased .…”
mentioning
confidence: 99%
“…4,5 The incidence of DGF is common in deceased donor transplants compared to living donor renal transplant recipients. 6 With increasing laparoscopic donor nephrectomy and warm ischaemia time, the incidence of ATN has increased. 7,8 Serum creatinine, a gold standard biochemical parameter for the laboratory diagnosis of kidney injury, increases late and after significant decline in glomerular filtration rate.…”
Serial uKIM-1 measurement can be used as non-invasive diagnostic biomarkers to predict the incident of DGF in living donor renal transplant recipients. At 18(th) post-transplant hour uKIM-1 can predict DGF with 100% specificity and 89.9% sensitivity with a cut-off value of normalized KIM-1 of 923.43 pg/mg.
“…Previous studies reported fairly high CIT in some current allocation systems; for example, CIT reported from United States, Turkey, and Tunisia, 21 ± 7, 14, and 18 to 23 hours, respectively (23)(24)(25).…”
Background: Delayed graft function (DGF) and slow graft function (SGF) are complications after kidney transplantation that resulted in poor short-term outcome. Objectives: In this study, we evaluate a new model for deceased kidney transplantation to reduce the cold ischemia time and its effect on DGF and SGF as short-term outcomes. Methods: We have included 814 deceased kidney transplanted patients in this study. All of the donors were local, while the recipients were both local and nonlocal. Kidney recipient's outcomes (included mortality rate as well as DGF and SGF), age, gender, BMI, blood group, Rh, allograft renal function, transplantation date, kidney transplantation history, PPD, positive history of rheumatologic disorders, the distance between home of recipient and the transplantation center, cardiovascular disease, and dialysis duration was evaluated for all patients. Results: The incidence of DGF and SGF were 24.8% and 20.5%, respectively. There were no statistical differences in the rate of DGF and SGF between local and distant recipients (P > 0.21). The rate of DGF was significantly higher in females as well as 40 -65 year old recipients (P < 0.05). In logistic regression multivariate analysis, DGF and SGF were significantly correlated with BMI, blood group, the history of kidney transplantation, and dialysis duration. Conclusions: This study showed the feasibility of using a local donor for a distant recipient as well as reduction of cold ischemia time and lower rate of DGF. It is obvious that the shorter CIT, which resulted from usage of local donor, can lead to better kidney transplant outcomes.
“…This finding was matched with some reports denoting that slow and delayed graft function are risk factors for T-cell and antibodymediated rejection 19 and the combination of both can affect patient survival. 20,21 Most of our patients were young females, and this was explained by Dörje and associates 2 who found that most of their patients with rejection were young and nonadherent with suboptimal immuno suppression.…”
Objectives: There are no comparable trials concerning the use of rituximab among renal transplant recipients with acute antibody-mediated rejection. Here, we compared early and late acute antibody-mediated rejection in renal transplant recipients in terms of response to rituximab therapy. Materials and Methods: Of 1230 kidney transplants performed at Hamed Al-Essa Organ Transplant Center (Kuwait) over the past 10 years, 103 recipients developed acute antibody-mediated rejections and were subcategorized into 4 groups according to the onset of rejection and rituximab treatment. All patients received the standard treatment for acute antibody-mediated rejection according to our protocol (plasma exchange and intravenous immunoglobulin). We added rituximab to the treatment regimen in 2 groups of patients: 27 patients with early rejection (group 1) and 38 patients with late rejection (group 2). Groups 3 and 4 represented nonrituximab groups, with 20 patients with early (group 3) and 18 patients with late rejection (group 4). We compared the 4 groups regarding graft and patient outcomes. Results: All patients were comparable regarding patient age, sex, pretransplant type of dialysis, viral profile, type of induction, donor criteria, and pretransplant comorbidities. We observed that delayed and slow graft function were significantly higher in groups 1 and 3 (P = .016); however, we found no significant differences in the 4 groups regarding new-onset diabetes after transplant, BK viral infection, and malignancy. Graft outcomes were significantly better in groups 1 and 2 than in groups 3 and 4 (P = .028). However, patient outcomes were comparable in the 4 groups (P > .05). Conclusions: Early acute antibody-mediated rejection in renal transplant recipients had significantly better outcomes when rituximab was added to the standard treatment regimen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.